SCHEMBL29327646

SCHEMBL29327646

CCc1ccc(-c2nc3cc(NC(=O)c4nc(C#N)ccc4S(C)(=O)=O)ccc3o2)cn1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 3/20 0.53
▸ MAPT P10636 14/20 0.44
▸ RXFP1 Q9HBX9 5/20 0.44
▸ TP53 P04637 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ THRB P10828 2/20 0.43
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP8 Q96LD8 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42
▸ SENP6 Q9GZR1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327625 0.89 PPARG (0.60) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327765 0.87 PPARG (0.57) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327620 0.86 TP53 (0.54) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327603 0.86 PPARG (0.61) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327637 0.83 PPARG (0.52) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327651 0.82 PPARG (0.51) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327616 0.82 TP53 (0.56) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327627 0.81 MAPT (0.57) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327840 0.81 PPARG (0.57) PPARGMAPTRXFP1TP53SMN1; SMN2
SCHEMBL29327624 0.79 MAPT (0.58) PPARGMAPTRXFP1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PPARG 1/4885MAPT 4591/4885RXFP1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback